StreetInsider.com News Articles

Spruce Biosciences Announces Data Presentation at the 18th International MPS Symposium

Thu, 28 May 2026 16:05:00 -0400

Nicole Muschol, M.D. to Present Long-Term Data on Tralesinidase Alfa (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB)

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that data on the long-term administration of its tralesinidase alfa enzyme replacement therapy (TA-ERT) for the treatment of Sanfilippo Syndrome Type B (MPS IIIB) will be presented at the 18th International MPS & Related Lysosomal Diseases Symposium, taking place June

Spruce Biosciences Announces Data Presentation at the 18th International MPS Symposium

Thu, 28 May 2026 16:05:00 -0400

Nicole Muschol, M.D. to Present Long-Term Data on Tralesinidase Alfa (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB)

Spruce Biosciences Announces Data Presentation at the 18th International MPS Symposium

Thu, 28 May 2026 16:05:00 -0400

Nicole Muschol, M.D. to Present Long-Term Data on Tralesinidase Alfa (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB)

Spruce Biosciences Announces Data Presentation at the 18th International MPS Symposium

Thu, 28 May 2026 16:05:00 -0400

Nicole Muschol, M.D. to Present Long-Term Data on Tralesinidase Alfa (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB)

Spruce Biosciences to Participate in Upcoming Conferences in June

Wed, 27 May 2026 16:05:00 -0400

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that members of the management team will present and participate in one-on-one meetings at upcoming conferences taking place in June.

Jefferies Global Healthcare Conference
Date and Time: June 4, 2026, at 11:05 a.m. ET
Format: Presentation and 1x1 meetings
Location: New York

Interested parties can access the live webcast for the Jefferies Global Healthcare Conference on the

Spruce Biosciences to Participate in Upcoming Conferences in June

Wed, 27 May 2026 16:05:00 -0400

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that members of the management team will present and participate in one-on-one meetings at upcoming conferences taking place in June.

Jefferies Global Healthcare Conference
Date and Time: June 4, 2026, at 11:05 a.m. ET
Format: Presentation and 1x1 meetings
Location: New York

Interested parties can access the live webcast for the Jefferies Global Healthcare Conference on the

Spruce Biosciences to Participate in Upcoming Conferences in June

Wed, 27 May 2026 16:05:00 -0400

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that members of the management team will present and participate in one-on-one meetings at upcoming conferences taking place in June.

Jefferies Global Healthcare Conference
Date and Time: June 4, 2026, at 11:05 a.m. ET
Format: Presentation and 1x1 meetings
Location: New York

Interested parties can access the live webcast for the Jefferies Global Healthcare Conference on the

Spruce Biosciences to Participate in Upcoming Conferences in June

Wed, 27 May 2026 16:05:00 -0400

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that members of the management team will present and participate in one-on-one meetings at upcoming conferences taking place in June.

Jefferies Global Healthcare Conference
Date and Time: June 4, 2026, at 11:05 a.m. ET
Format: Presentation and 1x1 meetings
Location: New York

Interested parties can access the live webcast for the Jefferies Global Healthcare Conference on the

Spruce Biosciences, Inc. (SPRB) PT Lowered to $230 at Oppenheimer

Wed, 27 May 2026 05:50:49 -0400

(Updated - May 27, 2026 5:50 AM EDT)

Oppenheimer analyst Leland Gershell lowered the price target on Spruce Biosciences, Inc. (NASDAQ: SPRB) to $230.00 (from $283.00) while maintaining a Outperform rating.

The analyst commented: "TA-ERT's Biologics License Application remains on track for a 4Q submission, following which we anticipate accelerated approval for MPS IIIB in mid-2027. We have revised our SPRB model to reflect our updated view of TA-ERT's market opportunity as well as account for share dilution following last month's financing. We reiterate our Outperform rating and lower our price target to $230 (from $283)."

Spruce Biosciences, Inc. (SPRB) PT Lowered to $230 at Oppenheimer

Wed, 27 May 2026 05:50:49 -0400

(Updated - May 27, 2026 5:50 AM EDT)

Oppenheimer analyst Leland Gershell lowered the price target on Spruce Biosciences, Inc. (NASDAQ: SPRB) to $230.00 (from $283.00) while maintaining a Outperform rating.